NASDAQ:ACHL • US00449L1026
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACHILLES THERAPEUTICS PL-ADR (ACHL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-04-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-04-05 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-12-14 | B of A Securities | Downgrade | Buy -> Underperform |
| 2023-08-07 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2022-12-07 | Chardan Capital | Maintains | Buy |
| 2022-12-07 | Piper Sandler | Maintains | Overweight |
| 2021-04-26 | Chardan Capital | Initiate | Buy |
| 2021-04-26 | Oppenheimer | Initiate | Outperform |
| 2021-04-26 | JP Morgan | Initiate | Underweight |
| 2021-04-26 | B of A Securities | Initiate | Buy |
| 2021-04-26 | Piper Sandler | Initiate | Overweight |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||
| EBITDA YoY % growth | -6.73M | -13.48M -100.30% | -32.96M -144.51% | -60.91M -84.80% | -74.19M -21.80% | -70.542M 4.92% | N/A -2.21% | N/A -38.96% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -6.9M | -13.78M -99.71% | -33.73M -144.78% | -64.2M -90.34% | -77.88M -21.31% | -75.255M 3.37% | N/A -2.83% | N/A -36.98% | N/A 49.73% | N/A -20.00% | N/A -20.00% | N/A -143.22% | N/A -7.65% | N/A 22.34% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -9.62 | -1.82 81.08% | -1.74 4.40% | N/A 89.45% | N/A 33.33% | N/A -2,183.33% | N/A 47.81% | N/A -17.48% | N/A | N/A | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 20.17% | -0.32 -5.40% | -0.24 40.29% | -0.17 63.88% | -0.16 55.56% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -24.072M -62.64% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -24.072M -23.36% | -13.77M 3.70% | -10.71M 39.83% | -7.65M 62.53% | -7.14M 70.34% |
All data in USD
6 analysts have analysed ACHL and the average price target is 6.12 USD. This implies a price increase of 313.51% is expected in the next year compared to the current price of 1.48.
ACHILLES THERAPEUTICS PL-ADR (ACHL) will report earnings on 2025-04-02, after the market close.
The consensus EPS estimate for the next earnings of ACHILLES THERAPEUTICS PL-ADR (ACHL) is -0.37 USD and the consensus revenue estimate is 0 USD.